NewsWhore
04-30-2009, 07:40 AM
<img alt="" height="1" width="1">
AstraZeneca Net Rose, Aided by Rival's Plant Shutdown (http://news.google.com/news/url?sa=T&ct=us/2-0&fd=R&url=http://www.bloomberg.com/apps/news%3Fpid%3D20601102%26sid%3Da.79d53RfU1Q%26refer%3Duk&cid=1343795739&ei=_o_5SZfCJKC4MYWHqZkI&usg=AFQjCNH-eNmCc2rP4GsFv0zmH_m01R9WoA)
Bloomberg
Profit was boosted by one-time gains including a currency windfall and the sale of US marketing rights to breast cancer treatment Abraxane. Manufacturing problems at Novartis AG's Sandoz unit, which makes cheaper versions of AstraZeneca's Toprol XL, ...
More... (http://news.google.com/news/url?sa=T&ct=us/2-0&fd=R&url=http://www.bloomberg.com/apps/news%3Fpid%3D20601102%26sid%3Da.79d53RfU1Q%26refer%3Duk&cid=1343795739&ei=_o_5SZfCJKC4MYWHqZkI&usg=AFQjCNH-eNmCc2rP4GsFv0zmH_m01R9WoA)
AstraZeneca Net Rose, Aided by Rival's Plant Shutdown (http://news.google.com/news/url?sa=T&ct=us/2-0&fd=R&url=http://www.bloomberg.com/apps/news%3Fpid%3D20601102%26sid%3Da.79d53RfU1Q%26refer%3Duk&cid=1343795739&ei=_o_5SZfCJKC4MYWHqZkI&usg=AFQjCNH-eNmCc2rP4GsFv0zmH_m01R9WoA)
Bloomberg
Profit was boosted by one-time gains including a currency windfall and the sale of US marketing rights to breast cancer treatment Abraxane. Manufacturing problems at Novartis AG's Sandoz unit, which makes cheaper versions of AstraZeneca's Toprol XL, ...
More... (http://news.google.com/news/url?sa=T&ct=us/2-0&fd=R&url=http://www.bloomberg.com/apps/news%3Fpid%3D20601102%26sid%3Da.79d53RfU1Q%26refer%3Duk&cid=1343795739&ei=_o_5SZfCJKC4MYWHqZkI&usg=AFQjCNH-eNmCc2rP4GsFv0zmH_m01R9WoA)